CMV INFECTIONS IN AIDS PATIENTS ON ANTI-VIRAL CLINICAL PROTOCOLS

(1)项目目标：由于CMV是公认的领先的 对艾滋病患者的机会性感染， 血液、尿液和组织标本来自于参加各种 CMV的临床试验。(2)临床主题 方案：（a）针对HIV-1的联合疗法：AZT/IL-2、IFN-α /IL 2，以及AZT、IFN和AZT/IFN组合的三组试验。（B） 一项随机双盲试验，以确定CMV-IG作为 预防艾滋病患者的CMV感染。 (c)I期试验， 用于预防和/或治疗CMV的胞嘧啶衍生物（HPMPC） 艾滋病患者的感染。 (d)腺嘌呤类似物的I期试验 （PMEA）作为对HIV-1和HIV-2具有双重抗病毒作用的潜在药物， 疱疹病毒。（患者群体：具有CD 4 < 200的AIDS）。 (e)另一 该项目的目标是确定CMV是否可以从 无症状和有症状的支气管灌洗标本 HIV-1患者。它可能提供了一个早期指标，重新激活的CMV， 这些患者，并导致早期开始抗CMV治疗， 预防全身暴发性疾病。 (3)主要发现：大多数试验 正在进行中。试验（a）的初步结果表明，CMV-IG确实 不能减少治疗患者的CMV病毒尿，可能无益 作为预防剂。

(1) Goals of Project: Since CMV is recognized as one of the leading opportunistic infections in AIDS patients, it is important to monitor blood, urine, and tissue specimens from patients enrolled in various clinical trials for the presence of CMV. (2) Subjects of Clinical Protocols: (a) Combination therapies against HIV-1 : AZT/IL2, IFN-alpha /IL2, and a three arm trial of combination AZT, IFN, and AZT/IFN. (b) A randomized double blind trial to determine the efficacy of CMV-IG as prophylaxis for CMV infections in AIDS patients. (c) Phase I trial with a Cytosine derivative (HPMPC) for the prevention and/or treatment of CMV infections in AIDS patients. (d) Phase I trial of an Adenine analog (PMEA) as a potential drug with dual anti- viral effects on HIV-1 and Herpes viruses. (patient population: AIDS with CD4 < 200). (e) Another goal of this project is to determine if CMV can be isolated from bronchial lavage specimens taken from asymptomatic as well as symptomatic HIV-1 patients. It may provide an early indicator of reactivated CMV in these patients, and lead to early initiation of anti-CMV treatment to prevent systemic fulminating disease. (3) Major Findings: Most Trials are ongoing. Preliminary results from trial (a) suggest that CMV-IG did not decrease CMV viruria in treated patients and may not be beneficial as a prophylactic agent.